Sustainability & Climate

FoodTrack is ditching calorie counting, blending AI with Traditional Chinese wellness to offer personalized health insights from photos of your meals, face, and tongue.

Beijing hails Xizang's economic boom, but critics point to a deep erosion of culture and rights. What is the true story of development on the roof of the world?

Highstar launches China's first overseas tabless battery factory in Malaysia, unveiling a high-performance cell for tools, robots, and future eVTOLs.

Swedish tech firm JLT leverages 30 years of industrial rugged computing to enter the defense market, aligning with national security and EU autonomy goals.

A new functional beverage with 500mg of Ashwagandha enters the UK, aiming to capture the growing market for mindful, non-alcoholic drink options.

Top execs from Hyundai, dealer associations, and policy groups will debate the future of EVs, trade, and affordability at a critical new NYIAS panel.

Chinese pet platform Boqii slashes losses by 75% despite falling revenue, betting its future on high-margin private labels and operational discipline.

Kansas City gets a taste of 2026 glory as the FIFA World Cup Trophy Tour arrives, kicking off a countdown to the world's biggest sporting event.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

Beyond roller coasters, a Japanese city is tackling demographic decline with English lessons and multicultural festivals to build a future chosen by the world.

New research on ILUMYA, LEQSELVI, and WINLEVI shows sustained efficacy and faster results, aiming to transform treatment for millions of patients.

Ten scholarly books are shortlisted for the prestigious 2026 Canada Prizes, tackling decolonization, urban crisis, and Canada's path forward.

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

A $520K state grant will provide firefighters with a new AI-powered blood test, highlighting a major push to protect high-risk first responders.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

Despite citizenship law debates, investor demand for Portugal's Golden Visa remains strong, signaling a strategic shift towards long-term residency.

FDA greenlights a novel, AI-discovered therapy for a Phase 1 trial, offering new hope for children with devastating central nervous system tumors.

As co-founder Jürgen Bickel steps down, 14-year veteran David Männer takes the helm to navigate Storz & Bickel's future and drive Canopy's U.S. plans.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.